Synergistic drug combinations prediction by integrating pharmacological data

Chengzhi Zhang\textsuperscript{a,b}, Guiying Yan\textsuperscript{a,b,∗}
\textsuperscript{a} Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing 100190, PR China
\textsuperscript{b} School of Mathematical Sciences, University of Chinese Academy of Sciences, Beijing, 100049, PR China

A R T I C L E   I N F O

Keywords:
Synergistic drug combinations
Factorization machines
Computational methods

A B S T R A C T

There is compelling evidence that synergistic drug combinations have become promising strategies for combating complex diseases, and they have evident predominance comparing to traditional one drug - one disease approaches. In this paper, we develop a computational method, namely SyFFM, that takes pharmacological data into consideration and applies field-aware factorization machines to analyze and predict potential synergistic drug combinations. Firstly, features of drug pairs are constructed based on associations between drugs and target, and enzymes, and indication areas. Then, the synergistic scores of drug combinations are obtained by implementing field-aware factorization machines on latent vector space of these features. Finally, synergistic combinations can be predicted by introducing a threshold. We applied SyFFM to predict pairwise synergistic combinations and three-drug synergistic combinations, and the performance is good in terms of cross-validation. Besides, more than 90% combinations of the top ranked predictions are proved by literature and the analysis of parameters in model shows that our method can help to investigate and explain synergistic mechanisms underlying combinatorial therapy.

1. Introduction

Synergistic drug combinations consist of two or more active pharmaceutical ingredients (APIs), which are developed to target multiple diseases or conditions, such as Exforge (amlodipine/valsartan). Accumulated studies have shown that synergistic drug combinations are widely used in the treatment of cancer, AIDs and other complex diseases \cite{12,16}. Christie M. Ballantyne et al. found that the therapeutic effect of the combination of ezetimibe and simvastatin (Vytorin) was significant for treatment of hypercholesterolemic patients \cite{3}. Zhong et al. have found that Homoharringtonine combining with arsenic trioxide could induce apoptosis of RPMI 8226 cell line \cite{63}. Drug combinations could improve medication compliance by reducing the pill burden of patients. Moreover, drug combinatorial therapy has better efficacy and smaller side effect than single drugs because of the fact that the development and progression of systemic diseases often involve in complex biological processes. Investments in synergistic drug combinations have emerged and become an increasingly important strategy because of the high failure rate in new drug development pipeline and high costs in marketing new drugs \cite{15}. It also has been argued that synergistic drug combinations played vital roles in drug development as a new paradigm of drug discovery \cite{24}.

Despite of more attentions have been paid to research on synergistic drug combinations, there are still a lack of effective prediction methods. Most synergistic combinations were found using exhaustive methods, such as high-throughput screening or pure experimental tests, which are time-consuming and costly. Therefore, a number of computational approaches for synergistic combinations prediction have been emerged with the growth of biological datasets \cite{36}. For example, Zhao et al. proposed a computational method to predict novel combinations by integrating molecular and pharmacological data, but its performance is limited by the feature constructed in this model \cite{62}. Ligeti et al. presented a prediction model by applying a propagation algorithm on a protein-protein association network \cite{38}, but the construction of network is affected by incompleteness of biological data. Sun et al. constructed support vector machines and naïve Bayesian classifiers on Hadoop for drug combination prediction, but it cannot explain synergistic mechanisms \cite{51}. Chen et al. collected synergistic antifungal drug combinations and construct the first Antifungal Synergistic Drug Combination Databases (ASDCD) \cite{10} and developed a semi-supervised algorithm implemented on drug-target interactions and drug chemical structures data \cite{11}, but its predictive performance is evaluated only on
antifungal drugs. Liu constructed features of drug pairs using some feature selection techniques and predicted potential synergistic drug combinations by applying random forest algorithm [41]. Based on drug target network and drug induced gene expression profiles [26], Li built a prediction model named by SyDra using random forest algorithm [37], which is a simple and effective computational model. However, it is a cancer-specific model and it was not tested on other diseases. Besides, most of these quantitative and qualitative prediction methods are proposed to pairwise synergistic combinations and cannot be applied to predict multi-drug synergistic combinations.

In this paper, by considering synergistic mechanisms as combinations of their pharmacological characteristics [8], we proposed a new model, namely SyFFM, to infer potential pairwise synergistic combinations and three-drug synergistic combinations. Drug targets, metabolic enzymes and ATC (Anatomical Therapeutic Chemical Classification System) were collected for constructing features of drug combinations and FFM (Field-aware Factorization Machines) [30] applied to calculate the synergistic scores. FFM models pairwise interactions via inner products of respective feature latent vectors, and it has good performance under huge sparsity. Using factorized parameters, FFM provides a new perspective to investigate interactions between drugs. SyFFM was evaluated on various datasets, and the good predictive performance suggests that it would help to identify novel drug combinations effectively. Analysis on the parameters of SyFFM demonstrates that the new model can provide insights to uncover the synergistic mechanisms.

2. Methods

Let $D = \{d_1, d_2, \ldots, d_n\}$ denotes the drug set, $T = \{t_1, t_2, \ldots, t_k\}$ be the target set, $E = \{e_1, e_2, \ldots, e_m\}$ be the enzyme set and $A = \{a_1, a_2, \ldots, a_p\}$ be the ATC set. For each drug pair $(d_i, d_j)$, $y_{ij}$ is defined to indicate their synergistic relationship, $y_{ij} = 1$ if $(d_i, d_j)$ is an approved synergistic combination, and $y_{ij} = -1$ if not.

2.1. Features construction

For each drug pair $(d_i, d_j)$, we constructed its feature vector $F_{ij} = (F_{ij}^F, F_{ij}^E, F_{ij}^{A})$ as follows,

1. Target pairs of $(d_i, d_j)$, $F_{ij}^T$: (i) Denote the targets of $d_i$ as $T_{d_i} = \{t_1\}$ and the target pairs of $(d_i, d_j)$ as $\{(t_k, t_l)\}_{k \in T_{d_i}}$. (ii) Collect the target pairs of all synergistic drug combinations, written $T_{syn} = \{(t_k, t_l)\}_i$. In other words, each pair $(t_k, t_l)$ in $T_{syn}$ is a target pair of at least one synergistic drug combination and the target pairs in $T_{syn}$ were sorted order by target ID. (iii) Construct a $0$–$1$ row vector $F_{ij}^T$ and $|F_{ij}^T| = \sum_{i=1}^{k} \sum_{j=1}^{n} \sum_{l=1}^{m} x_{ij}^k l$, where the $k$-th components of $F_{ij}^T$ is $1$ if the $k$-th target pair is one target pair of $(d_i, d_j)$. Otherwise, the $k$-th components of $F_{ij}^T$ is $0$.

2. Enzyme pairs of $(d_i, d_j)$, $F_{ij}^E$: The enzyme pairs of all synergistic drug combinations could be obtained according to drug-enzyme associations, recorded as $E_{syn}$. Sort the enzyme pairs in $E_{syn}$ by enzyme ID and construct a $0$–$1$ row vector $F_{ij}^E$. The components of $F_{ij}^E$ is set in a similar way as described above for the construction of $F_{ij}^T$.

3. ATC pairs of $(d_i, d_j)$, $F_{ij}^{A}$: The ATC pairs of all synergistic drug combinations could be obtained according to drug-ATC associations, recorded as $A_{syn}$. Sort the ATC pairs in $A_{syn}$ by ATC ID and construct a $0$–$1$ row vector $F_{ij}^{A}$. The components of $F_{ij}^{A}$ is set in a similar way as described above for the construction of $F_{ij}^T$.

4. Feature vector of $(d_i, d_j)$, $F_{ij}$: Concatenate three features together, and the feature vector of $(d_i, d_j)$ was denoted as $F_{ij} = (F_{ij}^F, F_{ij}^E, F_{ij}^{A})$. Here, $C_{ij} \in \{T(\text{target}), E(\text{enzyme}), A(\text{ATC})\}$ is referred to as a filed of feature $F_{ij}$ and each components $F_{ij}^k$ is referred to as a feature. It is worth noting that the features constructed by our method are very sparse due to incomplete pharmacological data and the fact that most drugs do not have the same targets, enzymes or ATC.

2.2. SyFFM on synergistic drug combinations prediction

Degree-2-polynomial mappings (Poly2) has been recorded as an effective approach to learn information implicit in feature conjunctions [7, 34]. Based on this, we can simplify synergistic mechanisms as combinations of pharmacological characteristics, and for each drug pair $(d_i, d_j)$, the combinations of features can be represented by a linear function

$$\phi(w, F_{ij}) = \sum_k \sum_l w_{ij,kl} f_{ij,k} f_{ij,l} + \sum_k w_{ij,k}$$

(1)

and $w_{ij,k}$ denoted the contribution values of feature interaction $f_{ij,k}$ and a single feature $f_{ij,k}^l$ to the synergistic relationship between $d_i$ and $d_j$, respectively. $\phi(w, F_{ij})$ is modeled to be an indicator to measure the strength of synergy between $d_i$ and $d_j$, so $\phi(w, F_{ij})$ should be learned approximating to the real label $y_{ij}$.

Unfortunately, the above function could not reflect the real interactions between different features accurately. Take feature interactions $f_{ij,k}$ and $f_{ij,l}^k$ for example, $f_{ij,k}$ may affect the interaction between $f_{ij,l}^k$ and $f_{ij,l}^l$. However, $w_{ij,kl}$ is independent from $w_{ij,k}$ in the above function and they could not capture this mutually dependent relationship.

So, we improved $\phi$ by implementing FFM, which replaces all interactions by mapping similar features to be embedded near each other into several latent spaces according to fields it belongs to. Thus, dot product between latent vectors would capture interactions related to similar features and interactions not recorded in the available dataset are also allowed to caught. Although higher order of interactions could be estimated, we only considered first and second order due to high computational complexity. In our dataset, each feature can be represented by three latent vectors $v_{T}, v_{E}, v_{A}$ and the contribution value of feature interaction $\langle f_{ij,k}, f_{ij,l}^k \rangle$ can be represented by product of their corresponding latent vectors, written by $\langle v_{C,T}, v_{C,E} \rangle$). The latent vectors would help to extract the potential interactions between two drugs and $\phi(w, F_{ij})$ can be rewritten as

$$\phi(v, w, F_{ij}) = \sum_k \sum_l \langle v_{C,T}, v_{C,E} \rangle f_{ij,k} f_{ij,l} + \sum_k w_{ij,k}$$

(2)

For example, the feature vector of a drug combination is $f = (f_{ij,k}, f_{ij,l})$, and $f_k \in T(\text{target})$, $f_l \in E(\text{enzyme})$, $f_k \in A(\text{ATC})$, then the interaction of features can be represented as follows,

$$\langle v_{T,F,T}, v_{E,F,T} \rangle f_{ij,k} + \langle v_{E,F,A}, v_{T,F,A} \rangle f_{ij,k} f_{ij,l} + \langle v_{E,F,A}, v_{E,F,A} \rangle f_{ij,k} f_{ij,l} + \langle v_{T,F,A}, v_{T,F,A} \rangle f_{ij,k} f_{ij,l}$$

(3)

Indicator $\phi(v, w, F_{ij})$ should be learned to approximate the real synergistic relationship $y_{ij}$. Logistic loss function is chosen to learn feature interactions, which is a widely used loss function to penalize incorrect predictions in classification problem. In addition, $l_2$-regularization terms are introduced to prevent overfitting of SyFFM and generalize SyFFM to other drugs not included in the available dataset. Thus, the problem of synergistic drug combinations prediction would be converted to learn $v$ and $w$ by solving the following optimization problem,

$$\min_{v,w} \sum_{ij} \log(1 + \exp(-y_{ij} \phi(v, w, F_{ij}))) + \frac{\lambda}{2} ||v||^2 + \frac{\lambda}{2} ||w||^2$$

(4)

We implemented stochastic gradient methods to derive the optimal solution of this optimization problem. Let $(v', w')$ be the optimum solution, and the synergistic score between $d_i$ and $d_j$ was defined as

68
3. Results

3.1. Prediction on pairwise synergistic drug combinations

SyFFM was implemented on three datasets respectively, DCDB data (including 946 approved pairwise synergistic drug combinations, 759 drugs from DCDB [40]), NData (68 approved pairwise synergistic combinations and 92 drugs from paper [28]) and FDA data (184 approved pairwise synergistic combinations and 238 drugs from FDA until November 2010). In DCDB, there are 287,661 possible pairs of 759 drugs and 3% were approved to be synergistic combinations. Similarly, there are 1% pairs in NData and 6% pairs in FDA data were approved to be synergistic combinations. In each dataset, we regarded these approved synergistic combinations as ‘positive samples’, and the ‘negative samples’ were obtained by sampling from the random pairs of all drugs. We set different ratios of positive-to-negative samples (1:1, 1:2, 1:3, 1:4, 1:5) and analysis the impact of ratios on performance of SyFFM.

Firstly, 5-fold cross validation was implemented to evaluate our method. To guarantee the nonrandom of the prediction results, we implemented our method on 50 different negative samples and the optimal parameters were adjusted by cross validation. We got average AUC (DCDB) = 0.925 (0.87 ~ 0.93), AUC (NData) = 0.876 (0.84 ~ 0.92), AUC (FDA) = 0.896 (0.86 ~ 0.92) (Fig. 1). Secondly, the synergistic scores obtained by our method were sorted in descending order, for DCDB data, SyFFM correctly retrieved all associations in the top-50, 100, 150 records. (Fig. 1).

Synergistic combinations in FDA were updated after November 2010 and the predictive ability of SyFFM for potential synergistic drug combinations prediction, and the three-drug synergistic combinations prediction to pairwise combinations, we implemented SyFFM and the pairwise

| Drug 1   | Drug 2 | Evidence of synergy |
|----------|--------|---------------------|
| ampicillin sodium | tazobactam | PMID:24041466 |
| esomeprazole magnesium | sodium bicarbonate | None |
| trandolapril | hydrochlorothiazide | ethinyl estradiol |
| dienogest | amiodipine besylate | lamivudine |
| eprosartan mesylate | tenofovir disoproxil | fumarate |
| nicin | atorvastatin calcium | None |
| trandolapril | ethinyl Estradiol | None |
| norelgestromin | Ethinyl Estradiol | None |
| Ethinyl estradiol | ethynodiol diacetate | None |
| desogestrel | Ethinyl estradiol | PMID:10095800 |
| niacin atorvastatin calcium | None |
| desogestrel | Ethinyl estradiol | PMID:9673846 |

3.2. The impact of ratios of positive-to-negative samples on performance of SyFFM

To test the impact of different proportions of positive and negative samples on the performance of SyFFM, we randomly selected different numbers of negative samples from all non-approved drug pairs. AUC, AUPR and F1 score are used and the result is shown in Table 2, which means that the performance of SyFFM is getting worse as the number of negative samples increased. According to the above analysis, we set the ratio of positive-to-negative to be 1:1.

3.3. Prediction on three-drug synergistic combinations

We also evaluated the performance of SyFFM on 295 approved three-drug synergistic combinations collected from DCDB, including 368 drugs. Each three-drug combination was regarded as three pairwise drug combinations, for example, three-drug combination (d1, d2, d3) was regarded as (d1, d2), (d1, d3) and (d2, d3). If (d1, d2, d3) is a synergistic combination, then three pairwise combinations are treated as synergistic combinations (we record this hypothesis as H). In this way, we converted three-drug synergistic combinations prediction to pairwise synergistic drug combinations prediction, and the three-drug combination is predicted as synergistic if and only if all the corresponding three pairwise drug combinations are predicted as synergistic combinations. By decomposing entire three-drug combinations of 368 drugs into pairwise combinations, we implemented SyFFM and the pairwise
combinations were predicted. Then three-drug combinations could be predicted by screening the corresponding pairwise combinations. We got AUC of 0.946 in terms of 5-fold cross validation on the entire pairwise combinations (Fig. 2(blue curve)) and AUC of 0.944 on the entire three-drug combinations (Fig. 2(yellow curve)).

3.4. Analysis of feature vectors of drug pairs

In order to verify the influences of features defined in our method, we used target pairs $F_t^k$, enzyme pairs $F_e^k$ or ATC pairs $F_{ATC}^k$ to be the feature vector of drug pair $(d_i, d_j)$. Then, field-aware factorization machines were implemented on pairwise drug combinations using the new feature vectors respectively. The average AUCs achieved using new feature vectors were 0.706, 0.679 and 0.855, respectively, which was shown in Fig. 3. The performance of our method was not satisfying in terms of AUCs under 5-fold cross validation, which indicates that interactions between features from different fields play important roles in synergistic mechanisms.

3.5. Analysis of parameters of SyFFM

The coefficients in function $\phi$ indicate the contribution values of the corresponding features or feature interactions. Incorporating biological knowledge, we analyzed coefficients obtained on the prediction of pairwise drug combinations.

We sorted coefficients of single features (i.e. the first order coefficients $w$) in descending way and found that the features corresponding to top-10 coefficients are all target pairs. The result is shown in Table 3.

It is shown on the table that these target pairs are keys to the mechanism of synergy. Since a target is involved in different biological pathways [9,19], the multiple interactions between different targets may be applied in treatment of other diseases. For example, the activation of progesterone receptor can also inhibit the growth of breast tumors by changing the synthesis of estrogen receptor chromatin [49,53]; both ACE and AR play an important roles in the regulation of plasma, and the American Diabetes Association also suggested using ACE inhibitors or AR inhibitors to treat diabetes [22,47]; sitagliptin, inhibitors of DDP-4, can regulate the expression of PPAR and may have a protective effect on myocardial cells [35]; both 5'-AMPK and DDP-4 are targets of polycystic ovary syndrome [55]. These findings show that our model finds important features of synergism and may help to explain the synergistic mechanism between two drugs.

3.6. Comparison with previous methods for predicting synergistic drug combination

Using DCDB data, we compared the prediction performance between SyFFM and Bai’s method proposed in Ref. [4]. Bai’s method is a synergistic drug combination prediction model by applying a novel improved naive Bayesian algorithm on various types of features (targets, side effects, pathways, enzymes, transporters). The comparison result of leave-one-out cross validation is shown in Table 4.

4. Conclusions

By representing drug combinations as combinations of their pharmacological characteristics, we proposed a computational synergistic drug combination prediction approach, namely SyFFM. The features of drug combinations are constructed by integrating pharmacologic data such as drug targets and enzymes, and the synergistic scores between drugs are obtained by implementing field-aware factorization machines. SyFFM achieves good performances by predicting pairwise synergistic drug combinations and three-drug synergistic combinations, and plenty of prediction results are validated by various databases and literature. We demonstrated that SyFFM provides biological explanations for the synergistic principles underlying combinatorial therapy and offers a new method for studies on synergistic mechanisms.

However, several potential limitations exist in SyFFM. Firstly, the performance of model is limited due to the incompleteness data about synergistic drug combinations. Secondly, SyFFM relies on the feature patterns enriched in synergistic combinations and other feature construction approaches may be more preferable to be adopted. It is worth noting that the strict hypothesis $\mathcal{H}$ would introduce unreasonable bias for n-drug combinations with n increases and the computation complexity would present to be an exponential growth. So we only test SyFFM on pairwise and three-drug combinations, and the application of SyFFM to multi-drug synergistic combinations still has to be improved further. How to build a better synergistic drug combinations prediction model by utilizing diverse knowledge on drugs remains an challenge for future research.
Table 3
Features and approved synergistic drug combinations corresponding to top-10 coefficients.

| Target 1          | Target 2         | Approved synergistic combination                         | Disease                        |
|-------------------|------------------|----------------------------------------------------------|--------------------------------|
| Progesterone       | Estrogen receptor| Estrogens, conjugated; Medroxyprogesterone acetate        | Symptoms of menopause [18]     |
| Angiotensin-        | Type-1 angiotensin II receptor (AR) (ACE)                 | Ethinyl Estradiol; Norethindrone| Contraception [1]               |
| DPP-4 + PPAR-γ     | Rosiglitazone; Saxaglitap                               | Diabetes Mellitus, Type 2 [23,32,53]                      |
| Glucocorticoid      | Beta-2 adrenergic receptor                              | Diabetes Mellitus [14,48]                                      |
| 5'-AMPK + DDP-4     | Alogliptin; Pioglitazone                                | Asthma, Bronchial [5,13,42]                                      |
| DNA Ribonucleoside-diphosphate reductase subunit M2 | Fluourouracil; SCI44                                    | Chronic Obstructive Pulmonary Disease; Asthma; Bronchiectasis [46,59] |
| Renin              | AR                                                          | Type 2 Diabetes mellitus [2]                                 |
| Progesterone        | GnRH-R                                                     | Colorectal cancer [40]                                         |
| Follicle-stimulating hormone receptor | Buserelin; Pregnyl                                      | Hypertension [40]                                              |
| Angiotensin-converting enzyme | Voltage-dependent calcium channel gamma-1 subunit | For initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms [40] |

Table 4
Comparison result of SyFPM and Bai's method using leave-one-out cross validation.

| Method               | Precision | Recall | F1 score | Accuracy |
|----------------------|-----------|--------|----------|----------|
| SyFPM                | 0.9983    | 0.4573 | 0.9213   | 0.9255   |
| Bai's method with targets | 0.9008    | 0.5000 | 0.6431   | 0.7034   |
| Bai's method with side effects | 0.6957    | 0.6400 | 0.6667   | 0.6800   |
| Bai's method with pathways | 0.6133    | 0.6216 | 0.6174   | 0.6238   |
| Bai's method with enzymes | 0.6018    | 0.8095 | 0.6904   | 0.6115   |
| Bai's method with transporters | 0.4815    | 0.7500 | 0.5865   | 0.5339   |

Acknowledgements

We thank anonymous reviewers for valuable suggestions and funding support by National Natural Science Foundation of China under Grant No.11631014.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.sysbio.2018.10.002.

References

[1] Archer DF, Nakajima ST, Sawyer AT, Wentworth J, Trupin S, Koltun WD, Gilbert RD, Ellman H. Norethindrone acetate 1.0 milligram and ethyl estradiol 10 microgram as an ultra low-dose oral contraceptive. Obstet Gynecol 2013;122:610–7.
[2] Aschner P, Chan J, Owens D, Picard S, Wang E, Dain M, Pilorget V, Echtay A. Insulin-like growth factor 1 stimulates MAPK activity during proliferation of T cells. J Biol Chem 2005;280(27):26012–9.
[3] Bai LX, Dai H, Xu Q. Prediction of effective drug combinations by an improved Naïve Bayesian algorithm. Int J Mol Sci 2018;19(2):467.
[4] Bodezato-Lukaszyk A, van Noord J, McAulay K, McIver T. Efficacy and safety profile of flavocine/forormetor combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial. Curr Med Res Opin 2013;29:579–88.
[5] Chang YK, Hsieh CJ, Chang KW. Training and testing low-degree polynomial data mappings via linear SVM. J Mach Learn Res 2010;11(11):1471–90.
[6] Chen D, Liu X, Yang Y, Yang H, Lu P. Systematic synergy modeling: understanding drug synergy from a systems biology perspective. BMC Syst Biol 2015;9(1):56.
[7] Chen L, Li BQ, Zheng MY, Zhang J, Feng KY, Cai YD. Prediction of effective drug combinations by chemical interaction, protein interaction and target enrichment of KEGG pathways. BioMed Res Int 2013:1–10. https://doi.org/10.1155/2013/723785.
[8] Chen X, Ren B, Chen M, Liu MX, Ren W, Wang QX, et al. ASCD: antifungal synergistic drug combination database. PloS One 2014;9(1):e86499.
[9] Chen X, Ren B, Chen M, Wang Q, Zhang J, Yan G. NILSS: predicting Synergistic Drug Combinations Based on Semi-supervised Learning. PloS Comput Biol 2016;12(7):e1004975.
[10] Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58(3):621–81.
[11] Corre J, Mansfield L, Pertseva T, Blazko V, Kaiser K. Efficacy and safety of flavocine/forormetor combination therapy in patients with moderate-to-severe asthma. Respir Med 2013;107:180–90.
[12] DeFronzo R, Burant C, Fleck P, Wilson C, Mekki Q, Pratley R. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus. JAMA Intern Med 2011;171:1615–22.
[13] Dickson M, Gagnon JP. The cost of new drug discovery and development. Discov Med 2009;4(2):172–9.
[14] Fouquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 2015;3(3).
[15] Fried L, Emanuele N, Zhang J, Brophy M, Conner T, Duckworth W, Leehey D, McCullough P. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892–903.
[16] Gambacciani M, Giapponi M, Cappagli B, Genazzani AR. Effects of low-dose continuous conjugated estrogens and medroxyprogesterone acetate on menstrual cycles, symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol 2001;185:1180–5.
[17] Goto S, Okuno Y, Hattori M, Nishioka T, Kanehisa M. LGAND: database of chemical mappings via linear SVM. J Mach Learn Res 2010;11(11):1471–90.
[18] Hammoud P, Polynou N, Alshegb J, Erb K, Mikkelsen A, Elbeck H, Papanikolaou E, Andersen C. Girha trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in inf patients. Hum Reprod 2013;28:2511–21.
[19] Hwang H, Sawada R, Murakata R, Kotsa M, Yamanishi Y. Large-scale prediction of synergistic drug combinations using drug efficacy and target profiles. J Chem Inf Model 2015;55(12):2705–16.
[20] Ji J, Feng Zh, Xiaohua Ma. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev 2009;28(8):111.
[21] Juan YC, Zhuang Y, Chin WS. Field-aware factorization machines for CTR prediction. JMLR 2015;16:2829–839.
[22] Kang Y, Yang Y, Yang H, Lu P. Systematic synergy modeling: understanding drug synergy from a systems biology perspective. BMC Syst Biol 2015;9(1):56.
prediction. ACM Conf Recommend Syst 2016:43–50.

[32] Karyekar C, Donovan M, Allen E, Fleming D. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. PGM (Postgrad Med) 2011;122:63–70.

[33] Karyekar C, Frederich R, Ravichandran S. Clinically relevant reductions in HbA1c without hypoglycemia: results across four studies of saxagliptin. Int J Clin Pract 2013;67:759–67.

[34] Kudo K, Mastumoto Y. Fast methods for kernel-based text analysis in proceedings of the 41st annual meeting of the association of computational linguistics. 2003.

[35] Lee TI, Kao YH, Chen YC, Huang JH, Hsu MI, Chen YJ. The dipeptidyl peptidase-4 inhibitor sitagliptin modulates calcium dysregulation, inflammation, and p38 in hypertensive cardiomyocytes. Int J Cardiol 2013;168:5390–5.

[36] Li J, Zheng S, Chen B, Butte AJ, Swamidass SJ, Lu Z. A survey of current trends in computational drug repositioning. Briefings Bioinf 2016;17(1):2–12.

[37] Li X, Xu Y, Hui C. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles. Artif Intell Med 2017 Nov;67:759–67.

[38] Ligeti B, Vera R, Lukács G, Győrfy B, Pongor S. Predicting effective drug combinations via network propagation. IEEE Biomed Circ Syst Conf (BioCAS) 2012:78–81.

[39] Liu Y, Hu B, Fu C, Chen X. DCDB: drug combination database. Bioinformatics 2010;26(4):587–8.

[40] Liu L, Chen L, Zhang YH. Analysis and prediction of drug-drug interaction by minimum redundancy maximum relevance and incremental feature selection. J Biomol Struct Dyn 2017;35(2):312–29.

[41] Bodzenta-Lukaszyk A, Pulka G, Dymek A, Bumbacea D, McIver T. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respir Med 2011;105:674–82.

[42] Nooan M, Rosenwasser L, Martin P. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs 2006;66:2235–54.

[43] Hamon M, Amant C, Bauters C, Richard F, Helbecque N, Fadlen E. Association of angiotensin converting enzyme and angiotensin II type 1 receptor genotypes with left ventricular function and mass in patients with angiographically normal coronary arteries. Heart 1997;77:502–5.

[44] Pratley R, Reusch J, Fleck P, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009;25:2361–71.

[45] Soh GN, Soh JN, Nadeem R, Sheikh R, Khan FA, Soh AA, Bhat HA, Bhat RA. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pac J Cancer Prev 2012;13:5047–52.

[46] Williams-Herman D, Johnson J, Teng R, Luo E, Davies M, Kaufman K, Goldstein B. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009;25:569–83.

[47] Worth H, Förster K, Eriksson G, Nihlén U, Peterson S. Budesonide added to for- moterol contributes to improved exercise tolerance in patients with copd. Respir Med 2010;104:1450–9.

[48] Zhao XM, Iskar M, Zeller G, Kuhn M, Van Noort V, Bork P. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput Biol 2011;7(12):e1002323.

[49] Zhou XJ, Zhou YH, Chen XH, Qian WB. Homoharringtonine combined arsenic tri-oxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research. Chin J Integrated Tradit West Med 2013;33(6):834–9.